Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Search
Chronic Kidney Disease
Chronic Kidney Disease
Dr. Anna Dieckmann and Dr. Lorenz Maier
Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Dominik Huber
Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Boehringer Ingelheim - Life Forward
Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Vetmedica, Inc. Opens New R&D Facility | Boehringer Ingelheim US
Find out more on the opening of Boehringer Ingelheim Vetmedica Inc's new research and development facility in Ames, Iowa.
Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures
Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.
Financial year 2018
Financial year 2018
Cognitive Impairment with Schizophrenia
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
Diabetes
Diabetes
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Our Mission
Our Story
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Expanded Access Programs
Expanded Access Programs
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Innovation in CNS Disease Research
Innovation in CNS Disease Research
Thinking differently could eradicate some areas of retinal disease
Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.